Fig. 10From: Cost utility analysis of cryopreserved amniotic membrane versus topical cyclosporine for the treatment of moderate to severe dry eye syndromeSensitivity analysis showing that if the probability of a positive clinical response to Cyclosporine A (Restasis) is >58% at month 6, then Cyclosproine A (Restasis) becomes the less expensive optionBack to article page